171 related articles for article (PubMed ID: 29280500)
1. Early improvement in PANSS-30, PANSS-8, and PANSS-6 scores predicts ultimate response and remission during acute treatment of schizophrenia.
Lin CH; Lin HS; Lin SC; Kuo CC; Wang FC; Huang YH
Acta Psychiatr Scand; 2018 Feb; 137(2):98-108. PubMed ID: 29280500
[TBL] [Abstract][Full Text] [Related]
2. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Acta Psychiatr Scand; 2018 Nov; 138(5):420-431. PubMed ID: 30168131
[TBL] [Abstract][Full Text] [Related]
3. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
[TBL] [Abstract][Full Text] [Related]
4. Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
Lin HS; Lin CH
J Affect Disord; 2019 Feb; 245():91-97. PubMed ID: 30368075
[TBL] [Abstract][Full Text] [Related]
5. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
[TBL] [Abstract][Full Text] [Related]
6. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
Masand P; O'Gorman C; Mandel FS
Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
[TBL] [Abstract][Full Text] [Related]
7. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
Leucht S; Zhao J
J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
[TBL] [Abstract][Full Text] [Related]
8. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
9. Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.
Correll CU; Zhao J; Carson W; Marcus R; McQuade R; Forbes RA; Mankoski R
J Am Acad Child Adolesc Psychiatry; 2013 Jul; 52(7):689-698.e3. PubMed ID: 23800482
[TBL] [Abstract][Full Text] [Related]
10. An early improvement threshold to predict response and remission in first-episode schizophrenia.
Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
[TBL] [Abstract][Full Text] [Related]
11. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review.
Samara MT; Leucht C; Leeflang MM; Anghelescu IG; Chung YC; Crespo-Facorro B; Elkis H; Hatta K; Giegling I; Kane JM; Kayo M; Lambert M; Lin CH; Möller HJ; Pelayo-Terán JM; Riedel M; Rujescu D; Schimmelmann BG; Serretti A; Correll CU; Leucht S
Am J Psychiatry; 2015 Jul; 172(7):617-29. PubMed ID: 26046338
[TBL] [Abstract][Full Text] [Related]
12. Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.
Subeesh V; Maheswari E; Singh H; Saraswathy GR; Reddy N; Chiranjeevi P
Int J Psychiatry Clin Pract; 2020 Sep; 24(3):309-314. PubMed ID: 32338556
[No Abstract] [Full Text] [Related]
13. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.
Østergaard SD; Lemming OM; Mors O; Correll CU; Bech P
Acta Psychiatr Scand; 2016 Jun; 133(6):436-44. PubMed ID: 26558537
[TBL] [Abstract][Full Text] [Related]
14. Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
Anghelescu IG; Janssens L; Kent J; de Boer P; Tritsmans L; Daly EJ; van Nueten L; Schmidt ME
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1043-50. PubMed ID: 22995972
[TBL] [Abstract][Full Text] [Related]
15. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.
Jäger M; Riedel M; Obermeier M; Schennach-Wolff R; Seemüller F; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Bottlender R; Möller HJ
Schizophr Res; 2010 May; 118(1-3):183-8. PubMed ID: 20181461
[TBL] [Abstract][Full Text] [Related]
16. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
Hopkins SC; Ogirala A; Loebel A; Koblan KS
Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
[TBL] [Abstract][Full Text] [Related]
17. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
O'Gorman C; Kapur S; Kolluri S; Kane J
Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
[TBL] [Abstract][Full Text] [Related]
18. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs.
Kubo K; Fleischhacker WW; Suzuki T; Yasui-Furukori N; Mimura M; Uchida H
Acta Psychiatr Scand; 2019 Feb; 139(2):108-116. PubMed ID: 30198163
[TBL] [Abstract][Full Text] [Related]
19. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials.
Stauffer V; Case M; Kollack-Walker S; Ascher-Svanum H; Ball T; Kapur S; Kinon BJ
Schizophr Res; 2011 Aug; 130(1-3):11-9. PubMed ID: 21489754
[TBL] [Abstract][Full Text] [Related]
20. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Tollefson GD; Andersen SW
J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
